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a b s t r a c t 
Objectives: Using antiseptics in wound care can promote healing by preventing and treating infection. 
However, using antiseptics can present many challenges, including issues with tolerability, inactivation 
by organic matter and the emergence of antimicrobial resistance/cross-resistance. This review discussed 
the key challenges in antisepsis, focusing on povidone-iodine (PVP-I) antiseptic. 
Methods: Literature searches were conducted in PubMed, in January 2019, with a filter for the previous 5 
years. Searches were based on the antimicrobial efficacy, antiseptic resistance, wound healing properties, 
and skin tolerability for the commonly used antiseptics PVP-I, chlorhexidine gluconate (CHG), polyhex- 
anide (PHMB), and octenidine (OCT). Additional papers were identified based on author expertise. 
Results: When compared with CHG, PHMB and OCT, PVP-I had a broader spectrum of antimicrobial ac- 
tivity against Gram-negative bacteria, actinobacteria, bacterial spores, fungi and viruses, and a similar and 
broad spectrum of activity against Gram-positive bacteria. PVP-I was also highly effective at eradicating 
bacterial biofilms, which is a vitally important consideration for wound care and infection control. De- 
spite a long history of extensive use, no resistance or cross-resistance to PVP-I has been recorded, which 
is in contrast with other antiseptics. Despite previous misconceptions, it has been shown that PVP-I has 
low allergenic properties, low cytotoxicity and can promote wound healing through increased expression 
of transforming growth factor beta. 
Conclusion: With increased understanding of the importance of tackling antimicrobial resistance and 
bacterial biofilms in acute and chronic wound care, alongside improved understanding of the challenges 
of antiseptic use, PVP-I remains a promising agent for the management of antisepsis. 
© 2020 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY-NC-ND license. 















Abbreviations: CFU, colony forming unit; CHG, chlorhexidine gluconate; ES- 
APE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobac- 
er baumannii, Pseudomonas aeruginosa, Enterobacter spp.; FBS, foetal bovine serum; 
DR, multidrug-resistant; MFS, major facilitator superfamily; MBC, minimum bac- 
ericidal concentration; MEM, Eagle’s Minimal Essential Medium; MIC, minimum 
nhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, 
ethicillin-sensitive Staphylococcus aureus; OCT, octenidine; PHMB, polyhexanide; 
HMG, polyhexamethylene guanidine hydrochloride; PVP-I, povidone-iodine; Qac, 
uaternary ammonium compounds; RF, reduction factor; TGF-beta, transforming 
rowth factor beta; VRE, VRSA, vancomycin-resistant; VSE, vancomycin-susceptible; 
HO, World Health Organization; XDR, extensively drug-resistant. 
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924-8579/© 2020 The Authors. Published by Elsevier B.V. This is an open access article u. Introduction 
The use of topical antimicrobial agents in wound care can dras-
ically aid the healing process by preventing and treating infec-
ions in wounds [1] . Antiseptics have a broad spectrum of activity
gainst bacteria, actinobacteria, fungi and viruses; they are there-
ore well suited for the treatment of wounds [2] . Their high ef-
cacy against both planktonic and sessile bacterial communities is
articularly desirable, as wound healing is often delayed by the for-
ation of biofilms, which are bacterial communities that are often
olerant to antibiotic treatments [3] . However, the use of antisep-
ics can present many challenges, including issues with tolerability,
nactivation by organic matter and the emergence of antiseptic re-
istance, where microbes are resistant to antiseptics [1] . nder the CC BY-NC-ND license. ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 



















































































































According to the World Health Organization (WHO), antimicro-
bial resistance is a priority for global health action and is one of
the biggest threats to health, food and security [4] . It is well es-
tablished that the prevalence of resistance to topical antibiotics is
increasing due to the misuse and overuse of these agents, in par-
ticular mupirocin and fusidic acid [5–8] . However, it is becoming
increasingly clear that resistance to some antiseptics is also on the
rise; this is therefore a key challenge that needs to be addressed
[9] . 
A major concern with the rising prevalence of antibiotic resis-
tance, defined as the resistance of microbes specifically to antibi-
otics, is the emergence of multidrug-resistant (MDR) nosocomial
infections. The ESKAPE pathogens ( Enterococcus faecium, Staphylo-
coccus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseu-
domonas aeruginosa, Enterobacter spp . ) are the leading cause of
nosocomial infections across the world [10] , with many ESKAPE
bacteria becoming MDR [10] . In an age of increasing resistance,
antiseptics might provide an alternative and viable option to ef-
fectively target these organisms. 
This article discusses key challenges in antisepsis, namely an-
timicrobial efficacy, antiseptic resistance, antibiotic and antisep-
tic cross-resistance, wound healing and tolerability, focusing on
povidone-iodine (PVP-I) in comparison with other commonly used
antiseptics. 
2. Methods 
This article resulted from a focus meeting on ‘antiseptics in
clinical practice’ held in December 2018, which was attended by all
but one of the authors. In order to expand the microbiology exper-
tise of the authors, Professor Surbhi Malhotra-Kumar (University of
Antwerp) was invited to co-author the article after this event. 
Six literature searches were conducted in PubMed in January
2019. A filter for the previous 5 years was used to identify recent
advances and challenges in topical antisepsis. Search terms were
chosen based on discussions during the focus meeting. Searches
were based on the commonly used antiseptics – PVP-I, chlorhex-
idine gluconate (CHG), polyhexanide (PHMB) or octenidine (OCT)
– with the following additional search terms (synonyms were in-
cluded in all searches): Search 1: «‘Antimicrobial spectrum’ OR
named microorganisms OR ‘biofilm’» AND «terms relating to ac-
tivity/efficacy»; Search 2: «‘Cross-resistance’ OR ‘drug-resistance’»;
Search 3: «‘ESKAPE’ OR individual ESKAPE organism names [ Entero-
coccus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acine-
tobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp.] OR
‘nosocomial isolate’ OR ‘nosocomial infection’ OR ‘hospital-acquired
infection’» AND «terms relating to activity/efficacy»; Search 4:
«‘Organic material’ OR ‘organic soil’ OR ‘Blood’ OR ‘in vivo’ OR ‘ex
vivo’ OR ‘real life’» AND «’efficacy’ OR ‘activity’ OR ‘inactivation’»;
Search 5: «‘Wound’ OR ‘burn’ OR ‘ulcer’ OR ‘wound healing’» AND
«‘effect’ OR ‘efficacy’ OR ‘activity’ OR ‘promote’ OR ‘prevent’»; and
Search 6: «‘Tolerability’ OR ‘cytotoxicity’ OR ‘irritation’ OR ‘pain’ OR
‘colour’ OR ‘apoptosis’ OR ‘allergy’ OR ‘adverse effects’». 
Based on their abstracts, only papers identified by the searches
that were considered directly relevant were included in this review
article. The manuscript included additional papers that were iden-
tified by authors outside of the literature search. Papers were con-
sidered relevant based on authors’ expertise in microbiology and
antisepsis in surgical and dermatological practice. 
3. Results and Discussion 
The results from the literature search are summarised in
Table 1 . .1. Antimicrobial efficacy of antiseptics 
.1.1. Antimicrobial spectrum 
As mentioned, the antimicrobial activity of antiseptics against
SKAPE pathogens is particularly desirable, given their leading role
n nosocomial infections [10] . PVP-I was found to be effective
gainst Acinetobacter baumannii ( A. baumannii ), Klebsiella pneumo-
iae ( K. pneumoniae ), methicillin-sensitive Staphylococcus aureus ( S.
ureus ) (MSSA), methicillin-resistant S. aureus (MRSA), Enterococcus
aecium ( E. faecium ), Enterobacter spp., and Pseudomonas aeruginosa
 P. aeruginosa ) ( Table 2 A) [11–15] . Similarly, CHG was found to be
ffective against some MDR Gram-negative organisms ( A. bauman-
ii, K. pneumoniae, Escherichia coli [E. coli] ), vancomycin-resistant
nterococci, Enterobacte r spp., and nosocomial MSSA, MRSA and E.
aecium isolates, although the efficacy of CHG against MDR K. pneu-
oniae and P. aeruginosa was variable ( Table 2 B) [ 11 , 13 , 16–19 ]. CHG
as found to have antimicrobial activity against MDR A. baumannii
nternational clone II (IC II), although less than for non-IC II isolates
20] . PHMB was found to be effective against all ESKAPE pathogens
nd had higher bactericidal activities against MRSA , carbapenem-
esistant K. pneumoniae , and ceftazidime-resistant Enterobacter spp.
han CHG ( Table 2 C) [21–23] . A slight bactericidal advantage over
HG was observed against vancomycin-resistant E. faecium (VRE),
iprofloxacin-resistant and levofloxacin-resistant Acinetobacter spp .,
nd MDR P. aeruginosa [21] . OCT was found to be effective against
ll ESKAPE pathogens, including MDR Gram-negative and Gram-
ositive pathogens associated with nosocomial infections such
s K. pneumoniae, Enterobacter cloacae, A. baumannii, P. aerugi-
osa , and antibiotic-resistant S. aureus epidemic clones ( Table 2 D)
24–29] . 
Overall, PVP-I had a broader spectrum of antimicrobial activ-
ty compared with other commonly-used antiseptics (PHMB, CHG
nd OCT), targeting a wider range of Gram-negative bacteria, fungi
nd viruses, and a similar and broad range of Gram-positive bac-
eria ( Table 3 ) [ 2 , 30 ]. Additionally (unlike PHMB, CHG and OCT),
VP-I exhibited antimicrobial activity against actinobacteria and
acterial spores. The differences in the spectrum of activity be-
ween antiseptics may be due to their varying mechanisms of ac-
ion. While PHMB, CHG and OCT primarily act via cell wall and
lasma membrane disruption, PVP-I has been found to have multi-
le mechanisms of action ( Figure 1 ) [31–35] . For example, PVP-I
nteracts with several enzymes, including viral enzymes such as
aemagglutinin, neuraminidase and sialidase [36] . Enzyme inhi-
ition may therefore be one example of why PVP-I is effective
gainst a wide range of viruses as well as bacteria. In contrast,
HG and PHMB have been found to primarily disrupt the viral
nvelope and have limited efficacy against non-enveloped viruses
 37 , 38 ]. 
.1.2. Effect of organic material on antiseptic efficacy 
The efficacy of antiseptics can be diminished by organic mate-
ial, such as blood, which is typically present in wounds [2] . Histor-
cally, the antimicrobial activities of wound antiseptics have been
ested using in vitro suspension tests, which do not accurately rep-
esent wound conditions [39] . Recently, a new phase 2/step 2 in
itro test method was proposed, in which wound antiseptics are
ested against microbial test suspensions pre-dried on a metal car-
ier; this setting is more representative of antiseptic treatment of
 wound than suspension tests [39] . Using this new phase 2/step
 method, the potentially inhibiting influence of organic material
as tested on PVP-I, CHG, PHMB, and OCT. PVP-I had the shortest
ime to efficacy against S. aureus, E. faecium and P. aeruginosa even
n the presence of blood ( Figure 2 ) [39] . Despite being widely used
s an antiseptic, CHG was a far less effective antiseptic than PVP-I
n the absence or presence of organic material ( Figure 2 ) [39] . 
R. Barreto, B. Barrois and J. Lambert et al. / International Journal of Antimicrobial Agents 56 (2020) 106064 3 
Table 1 
Ability of commonly used antiseptics to address key challenges in antisepsis. 
Challenge Povidone-iodine Chlorhexidine gluconate Polyhexanide Octenidine 
Broad antimicrobial spectrum Broad spectrum of activity 
against Gram-positive 
bacteria, Gram-negative 
bacteria, fungi and viruses 
[2] 
Broad spectrum of activity 
against Gram-positive 
bacteria. Narrow spectrum 
of activity against 
Gram-negative bacteria, 
fungi and viruses [2] 
Broad spectrum of activity 
against Gram-positive 
bacteria and Gram-negative 
bacteria. Narrow spectrum 
of activity against fungi and 
viruses [2] 
Broad spectrum of activity 
against Gram-positive 
bacteria. Narrow spectrum 
of activity against 
Gram-negative bacteria, 
fungi and viruses [2] 
Effective against ESKAPE 
pathogens 
Effective against all ESKAPE 
pathogens [ 11 , 14 , 15 , 43 ] 
Effective against most ESKAPE 
pathogens, excluding 
Klebsiella pneumonia 
(variable activity) and 
Pseudomonas aeruginosa 
(limited activity) 
[ 11 , 16 , 18-20 ] 
Effective against all ESKAPE 
pathogens [22-24] 
Effective against all ESKAPE 
pathogens [25-30] 
Effective in organic material Shortest time to efficacy 
against Staphylococcus 
aureus, Enterococcus faecium 
and Pseudomonas aeruginosa 
in the presence of blood 
[40] 
Less effective than PVP-I in 
the presence of organic 
material [40] 
Less effective than PVP-I in 
the presence of organic 
material [40] 
Less effective than PVP-I in 
the presence of organic 
material [40] 
Effective against biofilms Highly effective at eradicating 
biofilms, including MRSA, 
Klebsiella pneumoniae, 
Pseudomonas aeruginosa , and 
Candida albicans [14] 
Less effective at eradicating 
Acinetobacter baumannii, 
Escherichia coli, MRSA, and 
Pseudomonas aeruginosa in 
biofilms than free-form 
bacteria but higher efficacy 
in young vs. mature biofilms 
[ 44 , 45 ] 





MRSA, and VRSA biofilms 
[ 27 , 28 ] 
Lack of antimicrobial 
resistance/cross-resistance 
No observed antimicrobial 
resistance/cross-resistance 
[ 35 , 36 ] 
CHG resistance observed in 
Staphylococcus epidermidis, 
Acinetobacter baumannii and 
Mycobacterium abscessus . 
Cross-resistance to colistin 
has been observed 
[ 34 , 54-57 ] 
Reduced susceptibility of 
MRSA and associated 
cross-resistance to 
daptomycin has been 
observed [66] 
Repeated exposure to 
Staphylococcus aureus leads 
to bacterial resistance [59] 
Provides beneficial effects on 
wound healing 
Promotes wound healing 
through increased 
expression of TGF- β , 
neovascularisation and 
re-epithelialisation [73] 
Promotes healing of 
full-thickness skin wounds 
but can cause skin irritation 
[76] 
Induces inflammation in vitro, 
which may be detrimental 
for healing wounds [80] 
Has a greater efficacy for 




Allergy is largely 
overestimated and allergic 
reaction to PVP-I is rare [89] 
Allergic reaction is well 
recognised [89] 
Allergic reaction is rare [89] Allergic reaction is rare [89] 
Abbreviations: CHG, chlorhexidine gluconate; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aerugi- 
nosa, Enterobacter spp.; MRSA, methicillin-resistant Staphylococcus aureus ; PVP-I, povidone-iodine; VRSA, vancomycin-resistant Staphylococcus aureus ; TGF-beta, transforming 














































b  .1.3. Efficacy against biofilms 
In the real-world setting, bacteria predominantly exist as com-
unities of cells in biofilms. Biofilms are heterogeneous struc-
ures containing a variety of microorganisms surrounded by a pro-
ective matrix, which can attach to inert and organic surfaces
40] . A recent systematic review and meta-analysis found the
revalence of biofilms in chronic wounds to be 78.2%, suggesting
hat biofilms are present in the majority of chronic non-healing
ounds [41] . As some ESKAPE pathogens have been observed to
egin the formation of biofilms within 24 hours, acute wounds
re also often affected by biofilm formation [3] . The presence of
iofilms delays wound healing and biofilm microorganisms are
articularly resistant to host defences and antimicrobial treatment
 3 , 40 ]. As such, there is a vital need for antiseptics that are effec-
ive against biofilms in the treatment of both acute and chronic
ounds. 
Several studies have been conducted to assess the efficacy of
ommonly used antiseptics against biofilms, including PVP-I, CHG,
HMB, and OCT. Low-dose PVP-I (0.25% w/w) eradicated robust
iofilms of MDR S. aureus, K. pneumoniae, P aeruginosa , and Candida
lbicans in vitro [14] . Following dilution, PVP-I was more effective
han other topical antimicrobials at removing biofilms of P. aerug-
nosa and multi-species biofilms of MRSA and C. albicans [42] . Inddition, PVP-I completely eradicated both S. aureus and P. aerug-
nosa biofilms within 15 minutes of application, while CHG com-
letely eradicated S. aureus biofilms only [18] . 
CHG has been found to have antimicrobial activity against
treptococcus mutans biofilm, but has been found to be less effec-
ive than alexidine and cetrimide [43] . In a further study, CHG had
imited efficacy when acting on a multi-species biofilm ( K. pneumo-
iae, P. aeruginosa, S. aureus , and E. faecalis ), particularly in a simu-
ated wound-bed setting [19] . CHG was also less effective at erad-
cating A. baumannii, E. coli , MRSA, and P. aeruginosa in biofilms
han in their free form, but had higher efficacy in young versus
ature biofilms in another study [ 44 , 45 ]. 
Studies investigating the efficacy of PHMB against biofilms have
hown PHMB to be effective against MRSA biofilm in a porcine
ound model [22] . Wound cleansing with PHMB or saline solution
lso reduced the bacterial load in venous leg ulcers, with no differ-
nce between treatment groups; however, biofilm was still present
fter cleansing with PHMB or saline [23] . 
OCT rapidly inactivated S. aureus , MRSA and vancomycin-
esistant S. aureus biofilms on polystyrene plates, stainless steel
oupons and urinary catheters in the presence or absence of
erum proteins [26] . OCT was also effective against A. baumannii
iofilms on polystyrene, stainless steel and urinary catheters, and
4 R. Barreto, B. Barrois and J. Lambert et al. / International Journal of Antimicrobial Agents 56 (2020) 106064 
Table 2 
(A) Antimicrobial activity of povidone-iodine against ESKAPE pathogens. (B) Antimicrobial activity of chlorhexidine against ESKAPE pathogens. (C) Antimicrobial activity of 
polyhexanide against ESKAPE pathogens. (D) Antimicrobial activity of octenidine against ESKAPE pathogens. 
(A) 
Antiseptic Pathogen Efficacy 
Povidone-iodine Nosocomial MRSA, MSSA, Enterococcus 
faecium, Enterococcus faecalis 
7.5% solution effective (vs. before exposure) on all pathogens after 3 minutes of contact 
time in quantitative suspension test [11] 
Acinetobacter baumannii 10% solution effective (removal rate = 98.48%) after 60 seconds of contact time vs. skin 
culture taken prior, in topical application of artificially contaminated hands [12] 
Nosocomial 
Enterobacter spp., Klebsiella pneumoniae, 
Acinetobacter spp. 
10% solution ‘immediately’ effective on all pathogens vs. skin culture taken before topical 
application ( P < 0.001) [13] 
Biofilms of MSSA, Klebsiella pneumoniae, 
Pseudomonas aeruginosa 
All pathogens completely eradicated after 24 hours of incubation with 0.25% solution or 
0.25% gel, in biofilm eradication assay [14] 
Escherichia coli ATCC 25922 reference 
strain, nosocomial Acinetobacter 
baumannii 
4% PVP-I was effective ( > 5 log 10 reduction) against all pathogens in microplate assay [15] 
(B) 
Antiseptic Pathogen Efficacy 
Chlorhexidine Nosocomial 
MRSA, MSSA, Enterococcus faecium, 
Enterococcus faecalis 
4% solution was effective (vs. before exposure) on all pathogens after 3 minutes of contact 
time in quantitative suspension test [11] 
Nosocomial 
Enterobacter spp., Klebsiella pneumoniae, 
Acinetobacter spp. 
10% solution ‘immediately’ effective on all pathogens vs. skin culture taken ‘immediately’ 
before topical application ( P < 0.001) [13] 
Klebsiella pneumoniae 
0.005% chlorhexidine diacetate solution (urinary catheter maintenance solution) effective 
against all strains within recommended contact time (15 minutes) 
0.05% chlorhexidine gluconate solution (antiseptic mouthwash with ethanol and 4% 
isopropyl alcohol) effective against all strains within 15 minutes and all strains (except for 
NCTC13368) within 5 minutes 
0.5% CHG solution (pre-operative skin preparation) effective against all strains within 5 
minutes 
0.004–0.012% CHG solution (hand disinfectant with patented combination of antimicrobial 
agents) effective against all strains within 5 minutes 
0.06% CHG (antimicrobial skin cleanser/hand wash) effective against all strains within 5 
minutes [16] 
Extensively drug-resistant Pseudomonas 
aeruginosa , XDR Acinetobacter 
baumannii , XDR Klebsiella pneumoniae , 
MRSA, VRE 
0.5%, 1% and 2% solutions effective (99–100% reduction vs. pre-exposure) against XDR 
Pseudomonas aeruginosa , XDR Acinetobacter baumannii and XDR Klebsiella pneumoniae after 
15 seconds of contact time, and against MRSA and VRE after 1 minute of contact time in 
quantitative suspension test [17] 
3-day mature biofilms of Staphylococcus 
aureus and Pseudomonas aeruginosa 
0.015% solution completely eradicated (no viable cells/6 log 10 CFU reduction vs. before 
exposure, P < 0.001) Staphylococcus aureus biofilm and was effective (3.96 log 10 CFU 
reduction vs. before exposure, P < 0.01) against Pseudomonas aeruginosa biofilm after 15 
minutes exposure in ex vivo porcine skin explant model 
0.015% solution eradicated (no viable cells vs. before exposure, P < 0.001) both 
Staphylococcus aureus and Pseudomonas aeruginosa biofilms after 24 hours of exposure in 
ex vivo porcine skin explant model [18] 
Multi-species Klebsiella pneumoniae, 
Pseudomonas aeruginosa, Staphylococcus 
aureus and Enterococcus faecalis 
(1:1:1:1) biofilm 
After 24 hours of incubation with CHG solution: 
• 0.1% solution eradicated ( P < 0.01 vs. control) Staphylococcus aureus and Klebsiella 
pneumoniae , and significantly reduced Pseudomonas aeruginosa and Enterococcus faecalis 
( P < 0.01 vs. control) 
• 1% solution eradicated ( P < 0.01 vs. control) Staphylococcus aureus and Enterococcus 
faecalis and significantly reduced ( P < 0.01 vs. control) Klebsiella pneumoniae and 
Pseudomonas aeruginosa 
• 2% solution eradicated ( P < 0.01 vs. control) Pseudomonas aeruginosa, Staphylococcus 
aureus and Enterococcus faecalis and significantly reduced ( P < 0.01 vs. control) Klebsiella 
pneumoniae 
• 4% solution eradicated all pathogens ( P < 0.01 vs. control) 
Standard wiping technique with 2% CHG wipes: 
• 2% wipes significantly more effective ( P < 0.01 vs. isopropyl alcohol) than 70% IPA 
against Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus , and 
Enterococcus faecalis 
Biofilm embedded in artificial agar plate wound bed: 
• Sterile gauze soaked in 0.5% CHG significantly reduced( P < 0.01 vs. sterile gauze) 
Pseudomonas aeruginosa, Klebsiella pneumoniae and Enterococcus faecalis, and eradicated 
( P < 0.01 vs. sterile gauze) Staphylococcus aureus 
Commercially available Tulle Gras dressing impregnated with 0.5% CHG in soft white 
paraffin eradicated ( P < 0.01 vs. sterile gauze) Staphylococcus aureus but no significant 
reduction (vs. sterile gauze) in Pseudomonas aeruginosa, Klebsiella pneumoniae or 
Enterococcus faecalis [19] 
Acinetobacter baumannii international 
clone II (IC II) and non-IC II 
0.1% CHG solution effective against Acinetobacter baumannii IC II and Acinetobacter 
baumannii non-IC II (reduced below detection vs. before exposure, P < 0.05) after 30 
seconds of exposure [20] 
( continued on next page ) 
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Table 2 ( continued ) 
(C) 
Antiseptic Pathogen Efficacy 
Polyhexanide MRSA, MSSA, Klebsiella pneumoniae , 
carbapenem-resistant Klebsiella 
pneumoniae , and Enterobacter spp., 
ceftazidime-resistant Enterobacter spp., 
Enterococcus faecium, Acinetobacter spp., 
MDR and wide-type Pseudomonas 
aeruginosa , and VSE and VRE 
0.1–3.2% PHMG significantly more effective (based on MIC, P < 0.05) than chlorhexidine 
against MRSA, MSSA, Klebsiella pneumoniae, Enterobacter spp., Enterococcus faecium, 
Acinetobacter spp., and Pseudomonas aeruginosa in a modified Mueller-Hinton broth 
microdilution 
PHMG eradicated MRSA, carbapenem-resistant Klebsiella pneumoniae , ceftazidime-resistant 
Enterobacter spp., VRE, ciprofloxacin-resistant and levofloxacin-resistant Acinetobacter spp. 
and MDR Pseudomonas aeruginosa faster than CHG at 2 x MIC in time-kill suspension test 
Similar efficacy (based on MIC, P > 0.05) to CHG against VSE and VRE, wide-type 
ciprofloxacin-resistant and levofloxacin-resistant Acinetobacter spp. and wide-type and 
MDR Pseudomonas aeruginosa [21] 
MRSA biofilm 0.1 % PHMB + propyl-betaine solution was effective (97.85% reduction vs. baseline [ P < 
0.05], 99.64% reduction vs. sterile water [ P < 0.05] and P < 0.05 vs. octenidine) against 
MRSA biofilm after 3 days in an in vivo porcine wound model [22] 
Staphylococcus aureus and Pseudomonas 
aeruginosa dominated leg ulcers 
0.1% PHMB and 0.1% undecylenamidopropyl betaine reduced bacterial load (vs. baseline) of 
Staphylococcus aureus and Pseudomonas aeruginosa but was not significantly more effective 
( P > 0.05) than saline on venous leg ulcers of human patients [23] 
(D) 
Antiseptic Pathogen Efficacy 
Octenidine Antibiotic-resistant Staphylococcus aureus 
epidemic clones (MRSA, MSSA, 
high-level mupirocin-resistant MRSA, 
low-level mupirocin-resistant MRSA, 
mupirocin-susceptible MRSA, 
mupirocin-susceptible MSSA 
0.001% solution was effective (bacterial reduction of > 6 log 10 vs. before exposure) against 
all isolates after 30 sec exposure in quantitative suspension tests [24] 
MDR Gram-negative pathogens 
( Escherichia coli, Klebsiella pneumoniae, 
Enterobacter cloacae, Acinetobacter 
baumannii and Pseudomonas aeruginosa ) 
0.01% and 0.05% were fully effective (bacterial reductions of > 5 log 10 vs. before exposure) 
against all isolates after 1 min contact time [25] 
MSSA, MRSA and vancomycin-resistant 
Staphylococcus aureus planktonic cells 
and biofilms 
2 mM effective ( P < 0.05 vs. 0 mM) at inactivating planktonic cells and preventing biofilm 
formation of all pathogens 10 mM and 5 mM effective ( P < 0.05 vs. 0 mM negative 
control) against fully formed biofilms of all pathogens [26] 
Acinetobacter baumannii biofilms 0.3%, 0.6%, and 0.9% were effective ( P < 0.05 vs. 0% negative control) in significantly 
inactivating Acinetobacter baumannii biofilms on all tested surfaces in a microliter plate 
assay [27] 
Enterococcus faecalis biofilm 0.1% solution significantly more effective (greater proportion dead cells) against Enterococcus 
faecalis biofilm than 1% alexidine and 2% chlorhexidine in a root dentin disc biofilm model 
[28] 
Staphylococcus aureus, Pseudomonas 
aeruginosa and Klebsiella pneumoniae 
Effective against Staphylococcus aureus (3.8 log 10 reduction), Klebsiella pneumoniae (4.8 log 10 
reduction) and Pseudomonas aeruginosa (3.4 log 10 reduction) after 15 min exposure [29] 
Abbreviations: CFU, colony forming unit; CHG, chlorhexidine gluconate; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa, Enterobacter spp.; MDR, multidrug-resistant; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, 
methicillin-sensitive Staphylococcus aureus; PHMB, polyhexanide; PHMG, polyhexamethylene guanidine hydrochloride; PVP-I, povidone-iodine; VRE, vancomycin-resistant 
Enterococcus faecium ; VSE, vancomycin-susceptible Enterococcus faecium ; XDR, extensively drug-resistant 
Table 3 
Summary of the antimicrobial activity for povidone-iodine, polyhexanide, chlorhexidine, and octenidine. Adapted from 
Lachapelle et al. [2] 
Antiseptic Vegetative bacteria Bacterial 
spores 
Fungi Viruses 
Gram-positive Gram-negative Actinobacteria 
Povidone-iodine, 10% BC +++ , BS BC +++ , BS BC ++ SC ++ FC +++ , BS VC ++ , BS 
Polyhexanide BC +++ , BS BC +++ , BS NA NA FC ++ , NS VC + , NS 
Chlorhexidine gluconate BC +++ , BS BC +++ , NS NA NA FC ++ , NS VC + , NS 
Octenidine BC ++ , BS BC ++ , NS NA NA FC ++ , NS VC + , NS 
+ , weak; ++ , medium; +++ , high 


























as equally effective against biofilms of MDR and drug-susceptible
solates [27] . Interestingly, OCT had greater antimicrobial activity
gainst E. faecalis biofilm on root dentin discs than CHG and alexi-
ine [28] . 
.2. Antiseptic resistance 
Resistance to antiseptics can be intrinsic to the microorganism
e.g. impermeability or chromosomally-mediated inactivation) or 
cquired through mutation or acquisition of plasmids and trans-
osons (e.g. efflux pumps, mutation of the target site) [ 37 , 46 ]. De-
pite extensive clinical use of PVP-I over several decades, and rig-
rous testing of isolates, there have been no reports of resistancer increased bacterial tolerance to antiseptic treatment [ 34 , 35 ].
his favourable resistance profile is likely to be due to the fact
hat iodine has multiple modes of action ( Figure 1 ) [ 34 , 35 ]. Un-
ike PVP-I, CHG has been found to act on one specific bacterial
arget: the bacterial cell wall [47] . Therefore, adaptations in this
arget can result in resistance to CHG, as demonstrated by the
pregulation of major facilitator superfamily efflux pump genes
nd Qac (quaternary ammonium compounds) efflux proteins in
. pneumoniae and Staphylococci , respectively [ 33 , 48 ]. Despite the
act that recent reports have suggested that the use of CHG does
ot promote CHG resistance among pathogens [49–51] , there is
verwhelming evidence to the contrary in seven distinct studies
52–58] . 
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Figure 1. Povidone iodine ( PVP-I) acts on multiple bacterial targets and therefore no resistance or antibiotic cross-resistance has been reported [ 34 , 35 ]. CHG acts on one 
specific target: the bacterial cell wall [47] . Expression of acquired resistance genes leads to CHG resistance, and may also lead to cross-resistance to antibiotics [48] . Adapta- 
tions to the bacterial cell wall lead to greater resistance to CHG alongside vancomycin and daptomycin [ 33 , 58 , 70 ]. Abbreviations: CHG, chlorhexidine gluconate; QAC genes, 


















































t  MSSA and MRSA strains with reduced susceptibility to CHG
have been reported [52] , with a cross-sectional study showing that
CHG exposure was associated with reduced CHG susceptibility in
MRSA isolates [53] . The results of a European study suggest that
resistance to CHG is more common in MRSA than in MSSA [59] .
This may result from greater expression of QacA/B efflux pump
genes, which is the most common determinant of CHG resistance
in MRSA [60] . In recent reports, decreased susceptibility to CHG
has also been found among clinical isolates of Staphylococcus epi-
dermidis associated with surgical site infections [54] , and among
MDR clinical isolates of S. epidermidis from bloodstream infections
[55] . Clinical isolates of A. baumannii with reduced susceptibility
to CHG have been observed [56] , and clinically prevalent strains
of Mycobacterium abscessus that are resistant to CHG (but not to
PVP-I) have also been identified [57] . VRE appears to have devel-
oped resistance to CHG in Danish hospitals, where use of CHG is
widespread, highlighting a need for continued surveillance of the
emergence of resistance ( Figure 1 ) [58] . Interestingly, recent data
indicate that exposure to sub-lethal concentrations of CHG and tri-
closan may contribute to the emerging problem of antibiotic re-
sistance by stimulating horizontal transfer of antimicrobial resis-
tance genes between bacteria [ 48 , 61 , 62 ]. In one study, exposure of
E. coli to sub-lethal triclosan concentrations upregulated the sex
pilus-encoding TraA gene and promoted horizontal gene transfer to
a greater degree than lethal concentrations [61] . The induction oforizontal gene transfer and antiseptic resistance may involve an
rray of processes more complex than those following lethal doses
f CHG and triclosan. This includes disturbances in osmoregulation
nd respiratory activity, the dissipation of proton motive force, ox-
dative stress, the triggering of SOS responses, and the induction of
rror-prone DNA replication [ 48 , 61 , 63 , 64 ]. These reports of resis-
ance are of particular concern because exposure to sub-minimum
nhibitory concentrations (MICs) of CHG and triclosan is a common
ccurrence following the use of personal hygiene products [62] .
he true consequences of this exposure, within the human body
nd the environment, are currently unknown and more research is
eeded [62] . 
In a study investigating the antimicrobial activity of PHMB
gainst Gram-negative bacteria ( E. coli, K. pneumoniae, P. aerugi-
osa, Moraxella catarrhalis, Haemophilus influenza ) in the presence
r absence of antibiotics, no resistance and no antagonism with an-
ibiotics was observed [65] . Furthermore, reduced susceptibility of
RSA to PHMB was not observed following PHMB decolonisation
reatment in vivo. However, in the same study, prolonged step-
ise exposure to low concentrations of PHMB in vitro promoted
educed susceptibility of MRSA to PHMB [66] . 
In a cross-sectional study, no direct association was found be-
ween OCT exposure and reduced susceptibility in MRSA isolates
53] . Although another study found a demonstrable reduction in
he susceptibility of MRSA isolates following OCT exposure, the re-
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Figure 2. Required exposure time to achieve efficacy in the presence (log 10 RF ≥
3) and absence (log 10 RF ≥ 5) of organic material for (A) Staphylococcus aureus , (B) 
Enterococcus faecium and (C) Pseudomonas aeruginosa . Bacteria were dispersed in 
either aqueous solution, organic material solution (MEM [with Earl’s salts and L- 
glutamine] and 10% FBS) or 30% organic blood material solution (MEM [with Earl’s 
salts and L-glutamine] and 10% FBS with human erythrocytes). Stainless steel test 
carriers were placed in Petri dishes coated with the resulting test solutions, which 
were dried for 60 minutes. Antiseptic compounds or negative controls were then 
applied to the test carrier surface. Antiseptic action was terminated after 0.08 h, 
0.5 h, 3 h, 10 h, and 24 h. Bacteria were recovered and re-incubated, and the re- 
sulting CFU and log 10 RF determined. Adapted from Schedler et al. [39] . Abbrevi- 
ations: CFU, colony forming unit; CHG, chlorhexidine gluconate; FBS, foetal bovine 
serum; MEM, Eagle’s Minimal Essential Medium; OCT, octenidine; PHMB, polyhex- 





























































ulting MIC and minimum bactericidal concentration (MBC) were
till below clinical concentrations [59] . 
.2.1. Development of cross-resistance to last-line antibiotics 
Although there is concern about the development of resis-
ance to antiseptics themselves, a potentially greater concern is
ross-resistance between antiseptics and antibiotics [67] . Cross-
esistance can be defined as resistance to a particular antiseptic
hat results in concomitant resistance to antibiotics [33] . Exposure
f clinical K. pneumoniae isolates to CHG can lead to resistance to
HG, and also cross-resistance to the antibiotic colistin. As very
ew antibiotics, in particular colistin, are effective against the ma-
ority of carbapenem-resistant K. pneumoniae isolates, such loss of
olistin efficacy has serious implications for successful treatment
f MDR K. pneumoniae infections ( Figure 1 ) [33] . Whole genome
equencing analysis of CHG-adapted strains of K. pneumoniae has
hown genetic changes to the PhoPQ two-component signalling
ystem and/or a putative Tet repressor gene smvR . These genetic
hanges increase the activity of efflux pumps and explain the in-
reased CHG resistance. Cross-resistance to colistin following CHG-
daptation is likely due to upregulation of the operon containing
mrK . This alters lipopolysaccharide modification and reduces the
ipid A net negative charge, causing a reduced binding affinity of
olistin. Alongside this, phoPQ mutations that arise through CHG-
daptation are linked to lipid A modifications and further colistin
esistance [33] . In Gram-positive bacteria, the qac family of genes
ncode for the Qac efflux proteins, which play a role in the efflux
f CHG and antiseptic resistance. The qac genes are located on a
acterial plasmid that also encode multiple resistance genes, with
he use of CHG adding a selective pressure for bacteria that are
lso resistant to multiple antibiotics ( Figure 1 ) [48] . 
Wound infections due to Enterococcus spp. are increasing world-
ide and strains of E. faecium with tolerance to antiseptics have
egun to emerge [ 68 , 69 ]. Serial exposure to sub-inhibitory con-
entrations of CHG selects for VRE with reduced susceptibility to
HG, and also isolates with reduced susceptibility to daptomycin
 Figure 1 ) [70] . Furthermore, a clinical MDR E. faecium isolate with
olerance to CHG appears also to be tolerant to the antibiotic baci-
racin via the same genetic determinant [68] . Incubation of several
. aureus strains with sub-lethal doses of CHG for up to 14 days
id not decrease susceptibility to CHG in the majority of strains,
ut did result in cross-resistance to tetracycline in all isolates [71] .
Alongside the resistance issues observed with the use of CHG,
rolonged in vitro exposure to low concentrations of PHMB selects
or MRSA, with reduced susceptibility to PHMB and concomitant
esistance to daptomycin [66] . Exposing P. aeruginosa to increasing
oncentrations of OCT over several days lead to increased tolerance
o OCT and also CHG [72] . 
This research into cross-resistance between antiseptics and an-
ibiotics is promising. However, further investigation is needed to
nderstand the concentrations of antiseptics that are required for
he promotion of horizontal gene transfer, as this area is currently
oorly understood [62] . Research in this area is imperative, as in-
reasing antimicrobial resistance may have grave consequences as
athogens become more resistant to antibiotics and antiseptics. 
.3. Wound healing and skin tolerability 
When considering antiseptics for wound management, atten-
ion should be paid to their efficacy in reducing the microbial bur-
en and also their effect on the healing wound [73] . An ideal an-
iseptic for wound care should promote healing and exhibit good
ocal tolerability [34] . 






















































































































c  3.3.1. Wound healing 
In a rodent model of acute skin wounds, PVP-I treatment en-
hanced wound healing through increased expression of transform-
ing growth factor beta, neovascularisation and re-epithelialisation
[74] . PVP-I has also been found to have haemostyptic (an astrin-
gent that stops bleeding) and anti-inflammatory effects in peri-
apical surgery [75] and to reduce production of reactive oxygen
species by human polymorphonuclear neutrophils [76] . Compared
with controls, PVP-I significantly increased the healing rate of
chronic leg ulcers with no apparent cytotoxicity towards dendro-
cytes, with the densities in microvessels and dendrocytes higher
in PVP-I-assigned lesions than in those receiving silver sulfadiazine
or CHG [77] . Similarly, treating leg ulcers with hydrocolloid dress-
ings in combination with daily applications of PVP-I increased the
healing rate and reduced deleterious bacteria-related inflamma-
tion, alongside the reduction in inflammation caused by the in-
hibitory effect of PVP-I on leukotriene B4 and leukocyte extrava-
sation, compared with hydrocolloid alone [ 75 , 78 ]. 
A recent systematic review concluded that topical PHMB may
promote healing of chronic stalled wounds and alleviate wound-
related pain [79] . A preclinical study in mice indicated that PHMB
has favourable effects on microcirculation, angiogenesis and ep-
ithelialisation in wound healing [80] . Furthermore, topical appli-
cation of PHMB, but not OCT, increased microcirculation of the
human skin in vivo, which is important for wound healing [73] .
However, PHMB induced inflammation in vitro via activation of NF-
kB and subsequent cytokine secretion, which may be detrimental
for healing wounds [81] . OCT gel significantly reduced the size of
chronic venous leg ulcers compared with modern dressings [82] ,
and in a clinical study comparing the efficacy of OCT and silver
dressings, the rate of healing was faster and reduction in pain level
greater in the OCT group versus the silver group [83] . 
Cytotoxicity tests have shown that PVP-I is better tolerated by
murine fibroblasts than CHG, PHMB and OCT. Interestingly, treat-
ment with PVP-I led to a revitalisation of murine fibroblasts, which
was not observed with CHG, PHMB or OCT [84] . When tested on
human fibroblasts, PHMB, hydrogen peroxide, CHG and OCT were
100% cytotoxic at their MBC; in contrast, some cell viability re-
mained for PVP-I at the MBC [85] . Additional in vitro studies have
indicated cytotoxic effects of PVP-I, PHMB and CHG [86–89] . How-
ever, it should be noted that these experiments were not carried
out in vivo and many used considerably lower concentrations than
those used in clinical practice. In vitro experiments must therefore
be interpreted with caution, as they may not necessarily be re-
flective of clinical settings [34] . Further investigation of antiseptics
in wound management in vivo is required, using concentrations of
antiseptics as applied in clinical practice. 
3.3.2. Tolerability 
Allergy to PVP-I has historically been overestimated, mainly due
to confusion between allergy and irritation [90] . In a study that
retested all patients who reacted positively to a PVP-I patch test to
ensure that any false positives were not recorded, the prevalence
of allergic contact dermatitis caused by PVP-I was estimated to be
0.4% [90] . When comparing the allergenic properties of commonly-
used antiseptics, allergic contact dermatitis was rare for PVP-I, OCT
and PHMB, but more common for CHG [90] . There have also been
reports of urticarial and anaphylactic reactions for CHG, anaphy-
lactic reactions for PHMB, and aseptic tissue necrosis for OCT [90–
93] . In recent years there has been a surge in confirmed cases of
anaphylaxis caused by CHG, yet awareness of CHG as an allergen
has been found to be low [94] . Diagnosis is easy to miss but pre-
sentation can be severe and occur at any time [95] , and increased
awareness of CHG allergy is needed in healthcare settings [95] . In terms of irritation, PVP-I 10% was significantly less irritating
n the skin than CHG 5% [2] . Worryingly, cases of CHG-induced
hemical burns in very low birth weight infants have been re-
orted [96] . Recently, the irritative potency of selected antiseptics
as assessed using a semi-in vivo testing method (hen’s egg test
n chorio-allantoicmembrane); PHMB caused no irritation, while
HG solution and OCT gel caused severe irritation [97] . 
Unlike the other antiseptics discussed in this review, PVP-I is
ometimes associated with the induction of thyroid dysfunction.
lthough PVP-I has been shown to have a transient effect on thy-
oid function in some susceptible patients, there were no major
onsequences of this effect on the health of these patients [98] .
dditionally, further studies have shown that thyroid dysfunction
n those individuals exposed to iodine antiseptics does not differ
rom that found in the general population [98–103] . 
In addition to allergic reaction and irritation, the use of PVP-
 is often associated with pain. A prospective study investigating
he prevalence of adverse reactions to commonly used antiseptics
howed a transient burning sensation to be experienced by 4–7% of
atients, with no significant difference between antiseptics [104] .
 further study using mouse models showed PVP-I to cause pain
y stimulating a subset of sensory neurons that express TRPA1 and
RPV1 channels. The mechanisms by which antiseptics induce pain
re not fully understood and this finding improves the understand-
ng of the adverse effects of antiseptic use, while providing an in-
ight into potential methods of reducing pain for patients [105] . 
. Conclusions 
When treating wounds with antiseptics, a number of potential
hallenges need to be taken into consideration, including: antimi-
robial spectrum and efficacy in the real-world setting; antisep-
ic resistance and antimicrobial cross-resistance; effect on wound
ealing; and tolerability. Although CHG is the most widely used
ntiseptic, it has a number of undesirable properties such as its
ssociation with resistance/cross-resistance, reduced efficacy in the
resence of organic material and allergic reactions. 
When compared with other commonly used antiseptics – in-
luding CHG, PHMB and OCT – PVP-I had several advantages. PVP-I
ad the broadest spectrum of activity, was highly effective at elim-
nating ESKAPE pathogens and biofilms, and maintained efficacy in
he presence of blood, making PVP-I a highly desirable antiseptic
n the management of wounds and nosocomial infections. Further-
ore, in an era where resistance to antiseptics and antibiotics is
n the rise, a key feature of PVP-I that sets it apart from other an-
iseptics is the lack of resistance/cross-resistance attributed to this
ntiseptic. This is even more noteworthy given that PVP-I has been
idely used for decades. 
As discussed, an ideal antiseptic for wound care should not
nly reduce the microbial burden of a wound, but also promote
ound healing. PVP-I has been found to promote wound healing
hile exhibiting low levels of cytotoxicity. Furthermore, PVP-I has
een highly tolerated, with the prevalence of allergic reaction be-
ng 0.4%. Although pain can be experienced when using antiseptics,
his is not unique to PVP-I and increased understanding could lead
o improved techniques to manage any adverse side effects. 
Moving forwards, further research is needed to understand the
uture implications of cross-resistance between antiseptics and an-
ibiotics. Large and well-controlled trials of topical antiseptics in
ound care and skin infections are needed, as the rationale for
heir selection and use in clinical practice has largely been based
n empirical evidence and small clinical and pre-clinical studies.
inally, healthcare facilities need to be mindful of the issues asso-
iated with antiseptics, in particular resistance/cross-resistance, to








































































































nsure that wounds are effectively treated without causing detri-
ental effects. 
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